ProVerum, a spin-out of The Trinity College Dublin, is a medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office.
ProVerum is developing technology to treat benign prostatic hyperplasia (BPH), which is an enlargement of the prostate gland that causes difficulty with urination.
ProVerum was founded in 2016 by Conor Harkin and Ríona Ní Ghriallais. The company is headquartered in Dublin, Ireland.
ProVerum has developed ProVee, a nitinol expander that gently re-shapes the enlarged prostate alleviating the symptoms caused by BPH. ProVee is designed to be safely deployed in a doctor’s office setting in a simple procedure under local anaesthesia.
ProVerum received approval from the US Food and Drink Administration (FDA) to commence trials, after it demonstrated promising results in a feasibility study in Australia.
ProVerum is backed by Gilde Healthcare, Lightstone Ventures, Atlantic Bridge University Fund, Enterprise Ireland, HBAN Medtech Syndicate, Irrus Investments, Boole, Xenium Capital, and others. The company completed a €30M Series A round on Jan 11, 2022. This brings ProVerum's total funding to $38.2M to date.